Advanced search
Publication Cover
Journal of European CME Volume 9, 2020 - Issue 1
Submit an article Journal homepage
1,082
Views
2
CrossRef citations to date
0
Altmetric
Special Collection on Outcomes in CME/CPD

Feasibility of Integrating a Mobile Decision-Support App into a Multicomponent CME Initiative: Developing Clinician Competence at the Point of Care

Anne Jacobsona Independent CME/CPD Professional, Cocoa Beach, FL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5831-4390View further author information
ORCID Icon,
Cara L. Macfarlaneb Siyemi Learning, Manchester, UKORCID Iconhttps://orcid.org/0000-0001-8210-5823View further author information
ORCID Icon &
Eugene Pozniakb Siyemi Learning, Manchester, UKORCID Iconhttps://orcid.org/0000-0002-9744-1317View further author information
ORCID Icon
Article: 1834762 | Received 14 Sep 2020, Accepted 02 Oct 2020, Published online: 20 Oct 2020

References

  • Upadhyay V, Landman A, Hassett M. Mobile health applications in oncology. J Clin Oncol. 2020;38(15_suppl):e14115.
  • Tarricone R, Cucciniello M, Armeni P, et al. Mobile health divide between clinicians and patients in cancer care: results from a cross-sectional international survey. JMIR Mhealth Uhealth. 2019;7(9):e13584. .
  • Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):119–5. .
  • Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95–123. .
  • Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;14(4):247–249.
  • National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in partnership with the American Society of Clinical Oncology (ASCO). Management of immuno-therapy related toxicities (immune checkpoint-inhibitor related toxicities). Version 1.2018; Updated 2018 February 14.
  • Zon RT, Edge SB, Page RD, et al. American society of clinical oncology criteria for high-quality clinical pathways in oncology. J Oncol Pract. 2017;13(3):207–210. .
  • Accreditation Council for Continuing Medical Education. ACCME data report: steady growth in accredited continuing medical education – 2019; 2020. Available from: www.accme.org/2019datareport.
  • Da L, Teng Y, Wang N, et al. Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials. Front Pharmacol. 2019;10:1671–1680.
  • Jacob C, Sanchez-Vazquez A, Ivory C. Clinicians’ role in the adoption of an oncology decision support app in Europe and its implications for organizational practices: qualitative case study. JMIR Mhealth Uhealth. 2019;7(5):e13555.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.